Cell Therapy R&D and Manufacturing Global Market Report, First Edition: 2023-2028

DOWNLOAD SAMPLE REPORT

This report provides an overview of the cell therapy R&D and manufacturing market from 2023 to 2028. The cell therapy market, as defined in this report, is comprised of revenue from instruments, consumables, and software sold to academic, clinical, biopharma, CDMO and CRO customers, along with service revenues generated by CDMOs and CROs. This market is highly fragmented today, with top vendors providing consumables, instruments and services for cell therapy R&D and manufacturing (e.g., Lonza, Thermo Fisher, etc.)and many other mid-sized and smaller-sized players that provide either consumables or instruments. A number of new players are preparing to enter the market with commercialized platforms, as challenges in the development and commercialization of cell products calls for innovation in the tools supporting these therapeutics.

For this report, we leverage a combination of secondary research (e.g., analysis of quarterly and annual reports, earnings call transcripts, clinical trials, congress abstracts, company websites, etc.) and primary research (e.g., 31 interviews with cell therapy tools end-users from academia, biopharma, CROs, and CDMOs; 76 survey respondents across biopharma and academia) to assess the current and expected future adoption and utilization of cell therapy manufacturing tools and technologies, and to characterize the key market dynamics. From our research and analysis, we estimate that the cell therapy manufacturing market is ~$9.5B in 2023 and is expected to grow at 19% p.a. in the next 5 years, to reach ~23B by 2028.

For each of the subsegments analyzed, we present forecasted data from 2023-2028. In addition, we detail market drivers (e.g., increased automation of manufacturing platforms) and moderators (e.g., high COGS), market trends (interest in the development and commercialization of allogeneic cell therapies), a high-level customer breakdown (large biopharma, small biopharma, academia, CDMOs / CROs), and offer key information on top competitors. All analyses are based on publicly reported data and DeciBio research and analysis.*

This report features a survey of 76 stakeholders in the U.S., EU, APAC and RoW to understand, at a granular level, familiarity and current adoption of cell therapy manufacturing platforms (cell separation / enrichment, bioreactors, automated platforms, end-to-end platforms, non-viral gene editing platforms), current and expected use of CDMO and CRO services, manufacturing costs for autologous and allogeneic products, current and expected use of viral and non-viral techniques, and technologies and assays used for QC / QA purposes.

*Disclaimer: Some of the companies listed in the report maybe DeciBio consulting clients and customers.

‍

Technologies and Revenues Included:

• Consumable, instrument, and software revenues associated with the purchase of raw materials, cell manufacturing platforms or tools, or software used to run the      platforms / tools, from basic discovery to commercial manufacturing  
• Service revenues associated with the development of a cell therapy product (e.g.,process development, analytical development, or GMP manufacturing), typically    offered by CROs and CDMOs
• All cell types under investigation for use as a cell therapy product includingCAR-T, TCR-T, NK / NKT, stem cells, TILs, and myeloid cells
• All steps in the cell manufacturing process, including cell isolation, genetic modification, cell expansion, cryopreservation, and fill / finish
• Global sales of products and services to academic, clinical, biotech / pharmaceutical companies,CRO, and CDMO customers

‍

Technologies and Revenues Excluded:

• Instrumentation, assays, and reagents used upstream of cell manufacturing for plasmid and viral vector production
• Spend downstream of cell therapy manufacturing (e.g.,administration of therapy to patients)
• Extracellular vesicle-based therapeutics

‍

Segmentations Covered in Market Analysis:

‍

Customer:‍

• Large Biopharma
• Small Biopharma
• Academia
• CRO
• CDMO

‍

‍Products & Services:‍

• Consumables
• Instruments
• Software
• Process Development
• Analytical Development
• GMP Manufacturing

‍

Stage of Development:‍

• Basic Discover
• Preclinical
• Phase I
• Phase II
• Phase III
• Commercial (approved)

‍

Therapeutic Area:

• Oncology
• Neurology
• Immunological
• Rare Disease
• Other

‍

Cell Type:‍

• CAR-T
• TCR-T
• NK / NKT
• Stem Cell
• Other (e.g., TIL, CAR-M, etc.)

‍

Method:

• Autologous
• Allogeneic‍

‍

Geography:

• United States
• Europe
• APAC
• Rest of World (RoW)

‍

Companies Profiled in the Report:

• Bio-Techne
• Catalent
• Charles River
• Corning
• Creative Bioarray
• Cytiva
• Fujifilm Diosynth Biotechnologies
• Lonza
• Maxcyte
• Millipore Sigma
• Miltenyi Biotec
• Revvity
• Samsung Biologics
• Sartorius
• STEMCELL Technologies
• ThermoFisher
• Wilson Wolf
• WuXi AppTec